EAU 2017 | The role of chemotherapy and immunotherapy in CRPC

Dr Gerald Mickisch, MD from the Bremen Center of Operative Urology, Bremen, Germany discusses the current treatment landscape of prostate cancer. As patients are surviving the earlier stages of prostate cancer, physicians are facing more challenges to develop treatments for patients with advanced prostate cancer. The current standard of care is chemotherapy but there is a potential for immunotherapy to replace this in the future, especially checkpoint inhibitors. PD-L1 inhibitors have revealed data that seems to be promising for the future of immunotherapy in the treatment of prostate cancer. This interview was recorded at the European Association of Urology (EAU) conference 2017 in London, UK.